Ainos Inc AIMD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AIMD is a good fit for your portfolio.
News
-
Ainos Reports Full Year 2023 Financial Results
-
Thinking about buying stock in Senseonics Holdings, Ainos, Marpai, Rush Street Interactive, or Evgo?
-
Thinking about buying stock in SoundHound AI, Macy's, Ainos, Helius Medical Technologies, or Renalytix?
-
Thinking about buying stock in MMTec, Ainos, Jumia Technologies, Akero Therapeutics, or BioVie?
-
Small-Cap Growth Virtual Investor Conference Presentations Now Available for Online Viewing
-
Small-Cap Growth Virtual Investor Conference Agenda Announced for February 7th, 2024
-
Ainos Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase II Trial of its VELDONA Formulation Against Mild COVID-19 Symptoms
-
Ainos, Inc. to Present at Small-Cap Growth Virtual Investor Conference February 7th
Trading Information
- Previous Close Price
- $1.04
- Day Range
- $1.03–1.05
- 52-Week Range
- $0.79–6.10
- Bid/Ask
- $1.04 / $1.05
- Market Cap
- $6.39 Mil
- Volume/Avg
- 6,722 / 1.5 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 34.91
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- < 0.01%
Company Profile
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 46
- Website
- https://www.ainos.com
Valuation
|
Metric
|
AIMD
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.20 |
Price/Sales | 34.91 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
AIMD
|
|---|---|
Quick Ratio | 1.41 |
Current Ratio | 1.85 |
Interest Coverage | −94.50 |
Quick Ratio
AIMD
Profitability
|
Metric
|
AIMD
|
|---|---|
Return on Assets (Normalized) | −35.95% |
Return on Equity (Normalized) | −41.73% |
Return on Invested Capital (Normalized) | −36.63% |
Return on Assets
AIMD
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Mvsczvzh | Ctrqr | $185.4 Bil | |
SYK
| Stryker Corp | Mfskrlfx | Llll | $127.7 Bil | |
BSX
| Boston Scientific Corp | Khgjynz | Hjjvm | $107.6 Bil | |
MDT
| Medtronic PLC | Hfgymfhwj | Xvdmtmd | $105.9 Bil | |
DXCM
| DexCom Inc | Cmsgshzc | Nsf | $54.7 Bil | |
EW
| Edwards Lifesciences Corp | Fhcdjjnqg | Kbjfbq | $52.0 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Pqlqlkty | Qnl | $24.6 Bil | |
ALGN
| Align Technology Inc | Rgglrwpq | Ddwsx | $23.4 Bil | |
PHG
| Koninklijke Philips NV ADR | Mvxvptfj | Kyzgnbw | $18.7 Bil | |
PODD
| Insulet Corp | Ttrskrkd | Jnxrbd | $11.6 Bil |